News and Trends 2 May 2023 FDA fast track for Memo’s kidney transplant infection treatment Memo Therapeutics AG, a biotech company developing therapeutic antibodies, says the U.S. Food and Drug Administration (FDA) has granted fast track designation to AntiBKV, Memo Therapeutics’ lead antibody therapeutic that targets BK polyomavirus (BKV) infection commonly seen in renal transplant patients. AntiBKV has successfully completed a phase I clinical study and following FDA clearance has […] May 2, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2023 Astellas eyes ophthalmology field with $5.9B Iveric Bio takeover Astellas Pharma Inc., through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio, Inc., for $40 per share in cash for a total equity value of approximately U.S. $5.9 billion. Iveric Bio will become an indirectly wholly-owned subsidiary of Astellas. […] May 2, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2023 Schizophrenia injection gets FDA approval Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and MedinCell have announced the U.S. Food and Drug Administration (FDA) has approved UZEDY (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults. UZEDY is the first subcutaneous, long-acting formulation of risperidone that utilizes SteadyTeq, a copolymer technology proprietary to MedinCell that controls […] May 2, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2023 Single-molecule valve breakthrough could lead to early disease diagnosis Molecules are incredibly small – around one hundred millionth the size of a softball – and they move randomly in liquids, making it difficult to manipulate them in a single form. To overcome this challenge, “nanofluidic devices” that can transport molecules in extremely narrow channels, similar in size to one millionth of a straw, are […] May 2, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 2 May 2023 Generative AI in novel drug development Within months of its release, ChatGPT is finding use in almost all industries, including biotech, pharma, and healthcare. ChatGPT and other large language models like it belong to a family of artificial intelligence (AI) technologies dubbed generative AI. Based on statistical associations gathered from large datasets, generative AI models produce content similar to the data […] May 2, 2023 - 4 minutesmins - By Sachin Rawat Share WhatsApp Twitter Linkedin Email
News and Trends 28 Apr 2023 Brenus Pharma reveals ‘groundbreaking’ preclinical results for colorectal cancer and solid tumor drug Brenus Pharma has announced what it said are two groundbreaking presentations on STC-1010, the company’s first drug candidate for colorectal cancer (CRC), produced by Brenus Pharma’s STC (stimulated tumor-cells) technology platform. Innovative models for anti-tumor vaccine development were highlighted: Inovotion’s CAM (chorioallantoic model) in-ovo assay and Explicyte’s ex-vivo co-cultured assay, were used to characterize the […] April 28, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Apr 2023 Mezzion Pharma raises $40M for treatment option for heart surgery patients Mezzion Pharma, a rare disease focused pharmaceutical company, has secured nearly $40 million to fund FUEL-2, its confirmatory phase 3 clinical trial, along with future commercialization and regulatory submissions in other countries including Europe. Mezzion Pharma is looking to bring to market JURVIGO (udenafil), a highly selective, unique and potent phosphodiesterase type 5 (PDE-5) inhibitor, […] April 28, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Apr 2023 Vitalli Bio formed to focus on immunological disorders Aditum Bio has announced the formation of Vitalli Bio, a portfolio company created for the development of novel therapies for immunological disorders. Aditum Bio is a biotech investment firm cofounded in 2019 by former Novartis CEO Joe Jimenez and former president of the Novartis Institutes for BioMedical Research (NIBR) Mark Fishman. Vitalli Bio is being […] April 28, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Apr 2023 Six synthetic biology companies that have made a mark The consequences of the climate crisis coupled with soil degradation and its impact on food and water security, seem dire. But, as ambitious as it may sound, synthetic biology companies could alleviate some of the environmental burden that the planet faces. As it involves the redesigning of organisms by genetically engineering them to have new, […] April 28, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 28 Apr 2023 ADC firm Adcentrx Therapeutics aims for clinic after $38M boost Antibody-drug conjugate (ADC) biotech company Adcentrx Therapeutics has closed a $38 million Series A+ financing. The round was led by Eight Roads Ventures, with participation from F-Prime Capital, ABio-X, Delta Capital, Trinity Innovation Fund, and other strategic investors. Life Venture Partners and Lighthouse Capital acted as Adcentrx’s financial advisors. Adcentrx Therapeutics intends to use the […] April 28, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Podcast 28 Apr 2023Beyond Biotech podcast 43 This week’s podcast is sponsored by Scientist.com. The mainstream media in the past couple of months has picked up on artificial intelligence (AI). The coverage concentrates not so much on its uses, more it highlights the potential for conflict, and fears over AI developing too quickly, or ‘taking over humanity.’ Debates have sprung up around […] April 28, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 27 Apr 2023 Australian biopharma Telix banks on AI with Dedicaid acquisition Australian biopharma company Telix Pharmaceuticals Limited is expanding its artificial intelligence (AI) capability with the signing of an agreement to acquire Austria-based Dedicaid GmbH, a spin-off of the Medical University Vienna. Dedicaid’s core asset is a clinical decision support software (CDSS) AI platform capable of rapidly generating indication-specific CDSS applications from available datasets, for use […] April 27, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email